Inicio
Resultado de la búsqueda
1 búsqueda de la palabra clave 'geometric mean titers (GMTs)'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine / Ana María Guevara Zambrano
Título : Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2019 Títulos uniformes : Human Vaccines & Immunotherapeutics Idioma : Inglés (eng) Palabras clave : Human papillomavirus 9vHPV vaccine recurrent respiratory papillomatosis clinical trial geometric mean titers (GMTs) Resumen : Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. Mención de responsabilidad : Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan Ys Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg Referencia : Hum Vaccin Immunother. 2019;15(1):141-145. DOI (Digital Object Identifier) : 10.1080/21645515.2018.1514227 PMID : 30261146 En línea : https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1514227?journalCode=kh [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4174 Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine [documento electrónico] / Ana María Guevara Zambrano, . - 2019.
Obra : Human Vaccines & Immunotherapeutics
Idioma : Inglés (eng)
Palabras clave : Human papillomavirus 9vHPV vaccine recurrent respiratory papillomatosis clinical trial geometric mean titers (GMTs) Resumen : Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. Mención de responsabilidad : Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan Ys Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg Referencia : Hum Vaccin Immunother. 2019;15(1):141-145. DOI (Digital Object Identifier) : 10.1080/21645515.2018.1514227 PMID : 30261146 En línea : https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1514227?journalCode=kh [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4174 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000788 AC-2018-075 Archivo digital Producción Científica Artículos científicos Disponible